References
- Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal [Internet]. 2010;3(105):cm1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20086235
- Kobayashi Y, Yamamoto K, Saido T, et al. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci U S A [Internet]. 1990;87(14):5548–5552. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=54362&tool=pmcentrez&rendertype=abstract
- Zheng Y, Humphry M, Maguire JJ, et al. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation. Immunity. 2013;38(2):285–295.
- Freigang S, Ampenberger F, Weiss A, et al. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis. Nat Immunol [Internet]. 2013;14(10):1045–1053. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23995233
- Moon J-S, Lee S, Park M-A, et al. UCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis. J Clin Invest [Internet]. 2015;125(2):665–680. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4319445&tool=pmcentrez&rendertype=abstract
- Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol [Internet]. 2010;6(4):232–241. Available from: http://www.nature.com/doifinder/10.1038/nrrheum.2010.4
- Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature [Internet]. 2010;464(7293):1357–1361. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2946640&tool=pmcentrez&rendertype=abstract
- Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol [Internet]. 2013;14(8):812–820. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3720827&tool=pmcentrez&rendertype=abstract
- Elhage R, Maret A, Pieraggi M-T, et al. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E deficient mice. Circulation [Internet]. 1998;97(3):242–244. Available from: http://circ.ahajournals.org.ezp-prod1.hul.harvard.edu/content/97/3/242.long
- Devlin CM, Kuriakose G, Hirsch E, et al. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci U S A. 2002;99(9):6280–6285.
- Merhi-Soussi F, Kwak BR, Magne D, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res. 2005;66(3):583–593.
- Alexander MR, Moehle CW, Johnson JL, et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest. 2012;122(1):70–79.
- Isoda K, Sawada S, Ishigami N, et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2004;24(6):1068–1073.
- Kamari Y, Werman-Venkert R, Shaish A, et al. Differential role and tissue specificity of interleukin-1α gene expression in atherogenesis and lipid metabolism. Atherosclerosis [Internet]. 2007;195(1):31–38. Available from: http://www.sciencedirect.com/science/article/pii/S0021915006007003
- Bhaskar V, Yin J, Mirza AM, et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis [Internet]. 2011;216(2):313–320. doi:10.1016/j.atherosclerosis.2011.02.026.
- Libby P, Wyler DJ, Janicka MW, et al. Differential effects of human interleukin-1 on growth of human fibroblasts and vascular smooth muscle cells. Arteriosclerosis [Internet]. 1985;5(2):186–191. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3872118
- Bevilacqua MP, Pober JS, Wheeler ME, et al. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest [Internet]. 1985;76(5):2003–2011. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=424265&tool=pmcentrez&rendertype=abstract
- Montesano R. Leukocyte interleukins induce cultured endothelial cells to produce a highly organized, glycosaminoglycan-rich pericellular matrix. J Cell Biol [Internet]. 1984;99(5):1706–1715. Available from: http://jcb.rupress.org/cgi/content/long/99/5/1706
- Martin S, Maruta K, Burkart V, et al. IL-1 and IFN-gamma increase vascular permeability. Immunology. 1988;64(Feb):301–305.
- Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86(24):9717–9721.
- Galea J, Armstrong J, Gadsdon P, et al. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16(8):1000–1006.
- Clarke MCH, Talib S, Figg NL, et al. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res. 2010;106(2):363–372.
- Van Tassell BW, Raleigh JMV, Abbate A. Targeting interleukin-1 in heart failure and inflammatory heart disease. Curr Heart Fail Rep. 2015;12(1):33–41.
- Ikonomidis I, Lekakis J, Revela I, et al. Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J. 2005;26(16):1618–1624.
- Saitoh T, Kishida H, Tsukada Y, et al. Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris. J Am Coll Cardiol [Internet]. 2000;35(3):655–665. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0735109799005835
- Kilic T, Ural D, Ural E, et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart [Internet]. 2006;92(8):1041–1046. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1861097&tool=pmcentrez&rendertype=abstract
- Correia LC, Garcia G, Kalil F, et al. Prognostic value of TIMI score versus GRACE score in ST-segment elevation myocardial infarction. Arq Bras Cardiol [Internet]. 2014;103(2):98–106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25029471
- Tsimikas S, Duff GW, Berger PB, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014;63(17):1724–1734.
- Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet [Internet]. 1993;91(4):403–404. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8500797
- Olofsson PS, Sheikine Y, Jatta K, et al. A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta: interleukin-1receptor antagonist balance in atherosclerosis. Circ J [Internet]. 2009;73(8):1531–1536. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19574724
- Francis SE, Camp NJ, Dewberry RM, et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation. 1999;99(7):861–866.
- Vohnout B, Di Castelnuovo A, Trotta R, et al. Interleukin-1 gene cluster polymorphisms and risk of coronary artery disease. Haematologica [Internet]. 2003;88(1):54–60. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L36168855\nhttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=03906078&id=doi:&atitle=Interleukin-1+gene+cluster+polymorphisms+and+risk+of+coronary+artery+disease&stitle=Haematologica&
- Freitag D, Butterworth AS, Willeit P, et al. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2015;3(4):243–253.
- Dinarello CA, Simon A, Van Der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov [Internet]. 2012;11(8):633–652. Available from: http://www.nature.com/doifinder/10.1038/nrd3800
- Morton AC, Rothman AMK, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study. Eur Heart J [Internet]. 2014:377–384. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25079365
- Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc [Internet]. 2013;124:174–190. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3715939&tool=pmcentrez&rendertype=abstract
- Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739–2748.
- Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28(1):48–59.
- Raju NC, Yi Q, Nidorf M, et al. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolysis. 2012;33(1):88–94.
- Martínez GJ, Robertson S, Barraclough J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc [Internet]. 2015;4(8):e002128. Available from: http://jaha.ahajournals.org/lookup/doi/10.1161/JAHA.115.002128
- Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol [Internet]. 2013;61(4):404–410. doi:10.1016/j.jacc.2012.10.027.
- Verma S, Eikelboom JW, Nidorf SM, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord [Internet]. 2015;15:96. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4553011&tool=pmcentrez&rendertype=abstract
- Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev [Internet]. 2005;57(2):163–172. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15914465
- Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102(2):322–328.
- Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol. 1998;25(1):36–43.
- Nesher G, Osborn TG, Moore TL. Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis. Clin Exp Rheumatol. 1997;15(4):343–347.
- Montesinos MC, Takedachi M, Thompson LF, et al. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5’-nucleotidase: findings in a study of ecto-5’-nucleotidase gene-deficient mice. Arthritis Rheum. 2007;56(5):1440–1445.
- Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489.
- Bulgarelli A, Martins Dias AA, Caramelli B, et al. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol [Internet]. 2012;59(4):308–314. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22113347
- Thornton CC, Al-Rashed F, Calay D, et al. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis [Internet]. 2015:1–10. Available from: http://ard.bmj.com/cgi/doi/10.1136/annrheumdis-2014-206305
- Coomes E, Chan ESL, Reiss AB. Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol [Internet]. 2011;2011:503028. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3070167&tool=pmcentrez&rendertype=abstract
- Reiss AB, Cronstein BN. Regulation of foam cells by adenosine. Arterioscler Thromb Vasc Biol. 2012;32(4):879–886.
- Micha R, Imamura F, Wyler Von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362–1370.
- Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet [Internet]. 2002;359(9313):1173–1177. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11955534
- Franklin J, Farragher TM, Lunt M, et al. Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis. Ann Rheum Dis [Internet]. 2010;69(9):1660–1664. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20498206
- Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology. 2010;49(2):295–307.
- Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin [Internet]. 2008;24(2):469–480. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18179735
- Prodanovich S, Prodanowich S, Ma F, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–267.
- Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J [Internet]. 2013;166(2):199–207.e15. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3888829&tool=pmcentrez&rendertype=abstract
- Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta Mol Cell Res. 2011;1813(5):878–888.
- Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22(5):347–352.
- Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621–636.
- Croker BA, Krebs DL, Zhang J-G, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol. 2003;4(6):540–545.
- Yasukawa H, Ohishi M, Mori H, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003;4(6):551–556.
- Mauer J, Chaurasia B, Goldau J, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol [Internet]. 2014;15(5):423–430. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24681566
- Rose-John S. Il-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237–1247.
- Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375–3383.
- Diamant M, Rieneck K, Mechti N, et al. Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. FEBS Lett. 1997;412(2):379–384.
- Jones GW, McLoughlin RM, Hammond VJ, et al. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol [Internet]. 2010;184:2130–2139. doi:10.4049/jimmunol.0901528.
- Keidar S, Heinrich R, Kaplan M, et al. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol [Internet]. 2001;21(9):1464–1469. Available from: http://atvb.ahajournals.org/content/21/9/1464.long
- Huber SA, Sakkinen P, Conze D, et al. Interleukin-6 exacerbates early atherosclerosis in mice. Arter Thromb Vasc Biol [Internet]. 1999;19:2364–2367. Available from: http://atvb.ahajournals.org/content/19/10/2364\nhttp://atvb.ahajournals.org//subscriptions/\nhttp://atvb.ahajournals.org/
- Elhage R, Clamens S, Besnard S, et al. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17β-estradiol in apolipoprotein E-deficient mice. Atherosclerosis [Internet]. 2001;156(2):315–320. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11395027
- Van Lenten BJ, Wagner AC, Navab M, et al. Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem. 2001;276(3):1923–1929.
- Song L, Schindler C. IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis. 2004;177(1):43–51.
- Jones GW, McLeod L, Kennedy CL, et al. Imbalanced gp130 signalling in ApoE-deficient mice protects against atherosclerosis. Atherosclerosis. 2015;238(2):321–328.
- Schuett H, Oestreich R, Waetzig GH, et al. Trans-signaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32(2):281–290.
- Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation [Internet]. 2000;101(15):1767–1772. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10769275
- Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA [Internet]. 2001;286(17):2107–2113. Available from: http://jama.ama-assn.org/cgi/doi/10.1001/jama.286.17.2107\nhttp://www.ncbi.nlm.nih.gov/pubmed/11694151
- Luc G, Bard JM, Juhan-Vague I, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol. 2003;23(7):1255–1261.
- Fan Z-X, Hua Q, Li Y-P, et al. Interleukin-6, but not soluble adhesion molecules, predicts a subsequent mortality from cardiovascular disease in patients with acute ST-segment elevation myocardial infarction. Cell Biochem Biophys. 2011;61(2):443–448.
- Sarwar N, Butterworth AS. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–1213.
- Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet [Internet]. 2012;379(9822):1214–1224. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3316968&tool=pmcentrez&rendertype=abstract\nhttp://www.sciencedirect.com/science/article/pii/S014067361260110X.
- Ferreira RC, Freitag DF, Cutler AJ, Functional IL6R 358Ala Allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 2013;9(4):e1003444.
- Ferreira MAR, Matheson MC, Duffy DL, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet. 2011;378(9795):1006–1014.
- Luchtefeld M, Schunkert H, Stoll M, et al. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J Exp Med [Internet]. 2007;204(8):1935–1944. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2118681&tool=pmcentrez&rendertype=abstract
- Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6:189–195.
- Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis [Internet]. 2008;67(11):1516–1523. Available from: http://ard.bmj.com/content/67/11/1516.long
- Gabay C, Emery P, Van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550.
- McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis [Internet]. 2013:1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24368514
- Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther [Internet]. 2011;13(5):R141. Available from: http://arthritis-research.com/content/13/5/R141
- Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010;122(21):2183–2200.
- Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J [Internet]. 2000;14(13):2032–2039. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11023987
- Hiltunen MO, Laitinen M, Turunen MP, et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation. 2000;102(18):2262–2268.
- De Keyzer D, Karabina S-A, Wei W, et al. Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol. 2009;29(12):2041–2046.
- Wilensky RL, Shi Y, Mohler ER, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14(10):1059–1066.
- Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2523–2529.
- Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA [Internet]. 2009;302(4):412–423. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19622820
- Lp PLASC, Thompson A, Gao P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet [Internet]. 2010;375:1536–1544. ST – Lipoprotein–associated phospholipase. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=20435228
- Wang Q, Hao Y, Mo X, et al. PLA2G7 gene polymorphisms and coronary heart disease risk: a meta-analysis. Thromb Res. 2010;126(6):498–503.
- Polfus LM, Gibbs RA, Boerwinkle E. Coronary heart disease and genetic variants with low phospholipase A2 activity. N Engl J Med. 2015;372(3):295–296.
- Mohler ER, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl. J Am Coll Cardiol [Internet]. 2008;51(17):1632–1641. Available from: http://www.sciencedirect.com/science/article/pii/S073510970800569X
- Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118(11):1172–1182.
- White HD. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med [Internet]. 2014:140330050005008. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24678955.
- O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA [Internet].2014;312(10):1006–1015. Available from: http://jama.jamanetwork.com/article.aspx?articleid=1900827.
- Niessen H. Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res [Internet]. 2003;60(1):68–77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14522408
- Tietge UJF, Maugeais C, Cain W, et al. Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem. 2000;275(14):10077–10084.
- Webb NR, Bostrom MA, Szilvassy SJ, et al. Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23(2):263–268.
- Bostrom MA, Boyanovsky BB, Jordan CT, et al. Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol. 2007;27(3):600–606.
- Ait-Oufella H, Herbin O, Lahoute C, et al. Group X secreted phospholipase a2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2013;33(3):466–473.
- Fraser H, Hislop C, Christie RM, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol [Internet]. 2009;53(1):60–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19129734
- Shaposhnik Z, Wang X, Trias J, et al. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res [Internet]. 2009;50(4):623–629. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2656655&tool=pmcentrez&rendertype=abstract
- Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation. 1999;100(12):1280–1284.
- Liu P-Y, Li Y-H, Tsai W-C, et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J. 2003;24(20):1824–1832.
- Koenig W, Twardella D, Brenner H, et al. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26(7):1586–1593.
- Sabatine MS, Morrow DA, O’Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27(11):2463–2469.
- Holmes MV, Exeter HJ, Folkersen L, et al. Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. Circ Cardiovasc Genet [Internet]. 2014;7(2):144–150. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4212409&tool=pmcentrez&rendertype=abstract
- Guardiola M, Exeter HJ, Perret C, et al. PLA2G10 gene variants, sPLA2 activity, and coronary heart disease risk. Circ Cardiovasc Genet. 2015;8(2):356–362.
- Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet. 2009;373(9664):649–658.
- Rosenson RS, Elliott M, Stasiv Y, et al. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur Heart J. 2011;32(8):999–1005.
- Rosenson RS, Hislop C, Elliott M, et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol. 2010;56(14):1079–1088.
- Nicholls SJ, Kastelein JJP, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA [Internet].2014;311(3):252–262. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24247616.
- Tse K, Tse H, Sidney J, et al. T cells in atherosclerosis. Int Immunol [Internet]. 2013;25(11):615–622. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24154816\nhttp://intimm.oxfordjournals.org/content/25/11/615.full.pdf
- Mallat Z, Taleb S, Ait-Oufella H, et al. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res [Internet]. 2009;50(Suppl):S364–S369. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19050311
- Morris-Rosenfeld S, Lipinski MJ, McNamara CA. Understanding the role of B cells in atherosclerosis: potential clinical implications. Expert Rev Clin Immunol [Internet]. 2014;10(1):77–89. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4358742&tool=pmcentrez&rendertype=abstract
- Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2015;35(2):258–264.
- Chen S, Shimada K, Zhang W, et al. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J Immunol [Internet]. 2010;185(9):5619–5627. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20935201\nhttp://www.jimmunol.org/content/185/9/5619.full.pdf
- Erbel C, Chen L, Bea F, et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol. 2009;183(12):8167–8175.
- Cheng X, Taleb S, Wang J, et al. Inhibition of IL-17A in atherosclerosis. Atherosclerosis. 2011;215(2):471–474.
- Smith E, Prasad KMR, Butcher M, et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2010;121(15):1746–1755.
- Van Es T, Van Puijvelde GHM, Ramos OH, et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun. 2009;388(2):261–265.
- Taleb S, Romain M, Ramkhelawon B, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med [Internet]. 2009;206(10):2067–2077. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19737863
- Ait-Oufella H, Herbin O, Bouaziz J-D, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;207(8):1579–1587.
- Danzaki K, Matsui Y, Ikesue M, et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32(2):273–280.
- Erbel C, Akhavanpoor M, Okuyucu D, et al. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol [Internet]. 2014;193(9):4344–4355. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1400181
- Ghoreschi K, Laurence A, Yang X-P, et al. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol. 2011;32(9):395–401.
- Gisterå A, Robertson A-KL, Andersson J, et al. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med [Internet]. 2013;5(196):196ra100. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23903754
- Cheng X, Yu X, Ding Y-J, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127(1):89–97.
- Zhao Z, Wu Y, Cheng M, et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis. 2011;217(2):518–524.
- Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation [Internet]. 2009;119(10):1424–1432. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19255340
- Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570–577.
- Young MS, Horn EJ, Cather JC. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Rev Clin Immunol [Internet]. 2011;7(1):9–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21162644
- Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med [Internet]. 2015;373(14):1329–1339. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1412679
- Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. Jama. 2011;306(8):864–871.
- Pastrana JL, Sha X, Virtue A, et al. Regulatory T cells and atherosclerosis. J Clin Exp Cardiolog [Internet]. 2012;2012(Suppl 12):2. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3757946&tool=pmcentrez&rendertype=abstract
- De Boer OJ, Van Der Meer JJ, Teeling P, et al. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. Plos One [Internet]. 2007;2(8):e779. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17712427
- Maganto-Garcia E, Tarrio ML, Grabie N, et al. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation. 2011;124(2):185–195.
- Gräbner R, Lötzer K, Döpping S, et al. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp Med. 2009;206(1):233–248.
- Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med [Internet]. 2006;12(2):178–180. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16462800
- Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med [Internet]. 2008;263(5):489–499. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18410592
- Weber C, Meiler S, Döring Y, et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest. 2011;121(7):2898–2910.
- Nicoletti A, Paulsson G, Caligiuri G, et al. Induction of neonatal tolerance to oxidized lipoprotein reduces atherosclerosis in ApoE knockout mice. Mol Med [Internet]. 2000;6(4):283–290. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1949951&tool=pmcentrez&rendertype=abstract\nhttp://www.scopus.com/inward/record.url?eid=2-s2.0-0034170821&partnerID=tZOtx3y1
- Ait-Oufella H, Horvat B, Kerdiles Y, et al. Measles virus nucleoprotein induces a regulatory immune response and reduces atherosclerosis in mice. Circulation [Internet]. 2007;116(15):1707–1713. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17875970
- Klingenberg R, Lebens M, Hermansson A, et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arter Thromb Vasc Biol. 2010;30(5):946–952.
- Li X, Liu Z, Yan X, et al. Induction of regulatory T cells by high-dose gp96 suppresses murine liver immune hyperactivation. PLoS One. 2013;8(7):e68997.
- Herbin O, Ait-Oufella H, Yu W, et al. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arter Thromb Vasc Biol [Internet]. 2012;32(3):605–612. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22223728
- Grundtman C, Jakic B, Buszko M, et al. Mycobacterial heat shock protein 65 (mbHSP65)-induced atherosclerosis: preventive oral tolerization and definition of atheroprotective and atherogenic mbHSP65 peptides. Atherosclerosis. 2015;242(1):303–310.
- Steinmetz M, Ponnuswamy P, Laurans L, et al. The intravenous injection of oxidized LDL- or apolipoprotein B100 - coupled splenocytes promotes Th1 polarization in wildtype and apolipoprotein E - deficient mice. Biochem Biophys Res Commun. 2015;464(1):306–311.
- Hermansson A, Ketelhuth DFJ, Strodthoff D, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med. 2010;207(5):1081–1093.
- Habets KLL, Van Puijvelde GHM, Van Duivenvoorde LM, et al. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res. 2010;85(3):622–630.
- Hjerpe C, Johansson D, Hermansson A, et al. Dendritic cells pulsed with malondialdehyde modified low density lipoprotein aggravate atherosclerosis in Apoe−/− mice. Atherosclerosis. 2010;209(2):436–441.
- Choi J-H, Cheong C, Dandamudi DB, et al. Flt3 signaling-dependent dendritic cells protect against atherosclerosis. Immunity. 2011;35(5):819–831.
- Sage AP, Murphy D, Maffia P, et al. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity. Circulation. 2014;130(16):1363–1373.
- Ait-Oufella H, Sage AP, Mallat Z, et al. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ Res. 2014;114(10):1640–1660.
- Hermansson A, Johansson DK, Ketelhuth DFJ, et al. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation. 2011;123(10):1083–1091.
- Dinh TN, Kyaw TS, Kanellakis P, et al. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation. 2012;126(10):1256–1266.
- Dietrich T, Hucko T, Schneemann C, et al. Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells. Atherosclerosis. 2012;220(2):329–336.
- Mor A, Luboshits G, Planer D, et al. Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes. Eur Heart J. 2006;27(21):2530–2537.
- Hasib L, Lundberg AK, Zachrisson H, et al. Functional and homeostatic defects of regulatory T cells in patients with coronary artery disease. J Intern Med. 2016;279(1):63–77.
- Emoto T, Sasaki N, Yamashita T, et al. Regulatory/effector T-cell ratio is reduced in coronary artery disease. Circ J [Internet]. 2014;78(12):2935–2941. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25327882
- Wigren M, Björkbacka H, Andersson L, et al. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler Thromb Vasc Biol. 2012;32(8):2000–2007.
- Dietel B, Cicha I, Voskens CJ, et al. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis. 2013;230(1):92–99.
- Singer BD, King LS, D’Alessio FR. Regulatory T cells as immunotherapy. Front Immunol. 2014;5(Feb):46.
- Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127(-) regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol [Internet]. 2014. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24704576
- Trzonkowski P, Bieniaszewska M, Juścińska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− T regulatory cells. Clin Immunol. 2009;133(1):22–26.
- Chistiakov DA, Sobenin IA, Orekhov AN, et al. Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects. Front Physiol. 2014 May 5;196.
- Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med [Internet]. 2011;365(22):2055–2066. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22129252\nhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3727432
- Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067–2077.
- Ponnuswamy P, Van Vre EA, Mallat Z, et al. Humoral and cellular immune responses in atherosclerosis: spotlight on B- and T-cells. Vasc Pharmacol [Internet]. 2012;56(5–6):193–203. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22329947
- Paigen B, Morrow A, Brandon C, et al. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis [Internet]. 1985;57(1):65–73. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3841001
- Huber SA, Sakkinen P, David C, et al. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation. 2001;103(21):2610–2616.
- King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler Thromb Vasc Biol. 2002;22(3):456–461.
- King VL, Cassis LA, Daugherty A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am J Pathol [Internet]. 2007;171(6):2040–2047. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2111126&tool=pmcentrez&rendertype=abstract
- Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol [Internet]. 2003;163(3):1117–1125. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1868277&tool=pmcentrez&rendertype=abstract
- Lin Y, Chen Z, Kato S. Receptor-selective IL-4 mutein modulates inflammatory vascular cell phenotypes and attenuates atherogenesis in apolipoprotein E-knockout mice. Exp Mol Pathol. 2015;99(1):116–127.
- Binder CJ, Hartvigsen K, Chang M-K, et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest. 2004;114(3):427–437.
- Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med [Internet]. 2008;205(2):339–346. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2271006&tool=pmcentrez&rendertype=abstract
- Cardilo-Reis L, Gruber S, Schreier SM, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med. 2012;4(10):1072–1086.
- Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res [Internet]. 1999;85(8):e17–e24. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10521249
- Nishihira K, Imamura T, Yamashita A, et al. Increased expression of interleukin-10 in unstable plaque obtained by directional coronary atherectomy. Eur Heart J. 2006;27(14):1685–1689.
- Ammirati E, Moroni F, Magnoni M, et al. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol [Internet]. 2015;179(2):173–187. Available from: http://onlinelibrary.wiley.com/doi/10.1111/cei.12477/abstract\nhttp://onlinelibrary.wiley.com.libaccess.lib.mcmaster.ca/doi/10.1111/cei.12477/abstract\nhttp://onlinelibrary.wiley.com.libaccess.lib.mcmaster.ca/store/10.1111/cei.12477/asset/cei12477.pdf?v=1
- Jha HC, Divya A, Prasad J, et al. Plasma circulatory markers in male and female patients with coronary artery disease. Heart Lung [Internet]. 2010;39(4):296–303. doi:10.1016/j.hrtlng.2009.10.005.
- Mirhafez SR, Zarifian A, Ebrahimi M, et al. Relationship between serum cytokine and growth factor concentrations and coronary artery disease. Clin Biochem. 2015;48(9):575–580.
- Ibc T, Consortium CAD. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet. 2011;7(9):e1002260.
- Sampi M, Ukkola O, Paivansalo M, et al. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. J Am Coll Cardiol. 2008;52(17):1370–1378.
- Silveira A, McLeod O, Strawbridge RJ, et al. Plasma IL-5 concentration and subclinical carotid atherosclerosis. Atherosclerosis. 2015;239(1):125–130.
- McLeod O, Silveira A, Valdes-Marquez E, et al. Genetic loci on chromosome 5 are associated with circulating levels of interleukin-5 and eosinophil count in a European population with high risk for cardiovascular disease. Cytokine. 2016;81:1–9.
- Ishigami T, Abe K, Aoki I, et al. Anti-interleukin-5 and multiple autoantibodies are associated with human atherosclerotic diseases and serum interleukin-5 levels. Faseb J. 2013;27(9):3437–3445.
- Garcia G, Taillé C, Laveneziana P, et al. Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev. 2013;22(129):251–257.
- Van Gool F, Molofsky AB, Morar MM, et al. Interleukin-5 - producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood. 2014;124(24):3572–3576.
- Fisher EA. Regression of atherosclerosis: the journey from the liver to the plaque and back. Arterioscler Thromb Vasc Biol. 2016;36(2):226–235.